Summary: Wells Fargo & Company initiated coverage on enGene (NASDAQ:ENGN) with an overweight rating and a $30.00 price target. Several other research firms have also given positive ratings and price targets on the stock. Insiders recently sold shares of enGene. Institutional investors have been actively acquiring stakes in the company.
Full articleSummary: Wells Fargo initiated coverage of enGene Holdings (NasdaqCM:ENGN) with an Overweight recommendation, projecting a 145.66% upside based on the average one-year price target of $36.21. Various major shareholders hold significant ownership stakes in the company.
Full article